文献速递肥胖与代谢综合征糖尿病

基于肠促胰素的减重药物治疗:抗阻运动能否优化身体成分变化

Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?
PubMed 文献 · Diabetes Care · 2024-01-01

本叙述性综述指出,基于肠促胰素的减重药物(如GLP-1受体激动剂、GIP受体激动剂及多受体激动剂)在减重的同时可导致瘦体重快速显著丢失(约10%或约6 kg),而抗阻运动训练可大幅增加瘦体重(约3 kg)和力量(约25%)。作者提出,应将个体化抗阻运动训练作为肠促胰素治疗的辅助手段,以在减脂的同时保留瘦体重。

要点

  • 利拉鲁肽、司美格鲁肽、替尔泊肽和瑞他鲁肽在超重或肥胖成人中可诱导约15-24%的体重下降。
  • 这些药物也可导致瘦体重快速显著丢失约10%或约6 kg,相当于十年以上的衰老。
  • 持续超过10周的有监督抗阻运动训练可使男性和女性瘦体重增加约3 kg、力量增加约25%。

核心结论

  • 作者提出,应将个体化抗阻运动训练作为肠促胰素治疗的辅助手段,以在减脂的同时保留瘦体重、优化身体成分变化。
  • 在肠促胰素治疗期间保留瘦体重,可能减弱停用减重药物后的体重(及脂肪)反弹。

研究设计与样本

  • 叙述性综述,汇总肠促胰素类减重药物对身体成分影响及抗阻运动干预效果的相关研究。

主要发现

  • 利拉鲁肽、司美格鲁肽(GLP-1受体激动剂)、替尔泊肽(GLP-1和GIP受体双重激动剂)及瑞他鲁肽(GLP-1、GIP和胰高血糖素受体三重激动剂)在超重或肥胖成人中诱导约15-24%的体重下降,并对血压、胆固醇、血糖和胰岛素有有益影响。
  • 这些药物也导致瘦体重快速显著丢失约10%或约6 kg,与十年以上的衰老相当。
  • 持续超过10周的有监督抗阻运动训练干预可使男性和女性瘦体重大幅增加约3 kg、力量增加约25%。
  • 在低热量饮食后,有氧运动联合利拉鲁肽相比单独任一干预,改善体重下降的维持。

关键数值与推荐

  • 随机试验中GLP-1受体激动剂诱导显著体重下降,与GIP受体激动剂联合可能增强该效果。
  • 持续超过10周的有监督抗阻运动训练干预可使男性和女性瘦体重增加约3 kg、力量增加约25%。

临床怎么用

  • 作者提出,应将个体化抗阻运动训练作为肠促胰素治疗的辅助手段推荐,以在减脂的同时保留瘦体重。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This narrative review highlights the degree to which new antiobesity medications based on gut-derived nutrient-stimulated hormones (incretins) cause loss of lean mass, and the importance of resistance exercise to preserve muscle. Glucagon-like peptide 1 receptor agonists (GLP-1RA) induce substantial weight loss in randomized trials, effects that may be enhanced in combination with glucose-dependent insulinotropic polypeptide (GIP) receptor agonists. Liraglutide and semaglutide (GLP-1RA), tirzepatide (GLP-1 and GIP receptor dual agonist), and retatrutide (GLP-1, GIP, and glucagon receptor triple agonist) are peptides with incretin agonist activity that induce ∼15-24% weight loss in adults with overweight and obesity, alongside beneficial impacts on blood pressure, cholesterol, blood glucose, and insulin. However, these agents also cause rapid and significant loss of lean mass (∼10% or ∼6 kg), comparable to a decade or more of aging. Maintaining muscle mass and function as humans age is crucial to avoiding sarcopenia and frailty, which are strongly linked to morbidity and mortality. Studies indicate that supervised resistance exercise training interventions with a duration >10 weeks can elicit large increases in lean mass (∼3 kg) and strength (∼25%) in men and women. After a low-calorie diet, combining aerobic exercise with liraglutide improved weight loss maintenance compared with either alone. Retaining lean mass during incretin therapy could blunt body weight (and fat) regain on cessation of weight loss pharmacotherapy. We propose that tailored resistance exercise training be recommended as an adjunct to incretin therapy to optimize changes in body composition by preserving lean mass while achieving fat loss.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024. PMID: 38687506. doi:10.2337/dci23-0100

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。